Press Releases

Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Tuesday, May 10

REHOVOT, Israel, and BRIDGEWATER, New Jersey, April 26, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the first quarter ended March 31, 2017 on Tuesday, May 9th after market close, and will host a corporate update conference call and webcast on Wednesday, May 10th, at 8:30am Eastern Time.

404614LOGO

Conference Call & Webcast
Tuesday, May 10, 2016 @ 8:30 am Eastern Time
Toll Free: 888-438-5519
International: 719-457-1506
Conference ID: 2254081
Webcast: http://public.viavid.com/index.php?id=124151

Replays, Available through May 24th:
Toll-Free: 844-512-2921
International: 412-317-6671
Conference ID: 2254081

About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit www.foamixpharma.com.

Contact:                                                    
Ilan Hadar, CFO    
LifeSci Advisors, LLC
+972-8-9316233                                    
ilan.hadar@foamixpharma.com                 

US Investor Relations
Michael Rice
LifeSci Advisors, LLC
+1-646-597-6979
mrice@lifesciadvisors.com

 

SOURCE Foamix Pharmaceuticals Ltd